Domov › Nemalicelični pljučni rak › South Carolina

Klinične študije za Nemalicelični pljučni rak v South Carolina

30 študij za Nemalicelični pljučni rak išče udeležence na lokacijah v South Carolina.

Mesta v South Carolina

Uradno besedilo študije (angleško)

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Medical University of South Carolina /ID# 273272, Charleston
Saint Francis Cancer Center - Greenville /ID# 276368, Greenville

Vključevanje udeležencevFaza 2

Starost 18 in več · Vsi spoli · Posodobljeno 5. okt. 2026 · NCT06568939

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Saint Joseph's/Candler - Bluffton Campus, Bluffton
Prisma Health Cancer Institute - Spartanburg, Boiling Springs
Bon Secours Saint Francis Hospital, Charleston
in še 15

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 5. okt. 2026 · NCT04267848

Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

Bon Secours Hematology and Oncology, Greenville

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT06472245

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

Exelixis Clinical Site #9, Myrtle Beach

Vključevanje udeležencevFaza 1

Starost 18 in več · Vsi spoli · Posodobljeno 1. okt. 2026 · NCT05176483

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Prisma Health Cancer Institute - Spartanburg, Boiling Springs
Prisma Health Cancer Institute - Easley, Easley
Gibbs Cancer Center-Gaffney, Gaffney
in še 9

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 1. okt. 2026 · NCT06498635

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

Saint Joseph's Candler Health System ( Site 4010), Bluffton
Medical University of South Carolina-Hollings Cancer Center ( Site 0045), Charleston

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT06312137

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Medical University of South Carolina, Florence
Medical University of South Carolina Health Lancaster Medical Center, Lancaster

Vključevanje udeležencevFaza 3

Starost 18–100 · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT05920356

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Medical University of South Carolina, Charleston

Vključevanje udeležencevFaza 2

Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT06667076

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

Medical University of South Carolina, Charleston
Lexington Medical Center, West Columbia

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 24. sep. 2026 · NCT06890598

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

Research Site, Greenville

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 23. sep. 2026 · NCT06357533

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

St Francis Cancer Center, Greenville

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT06875310

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

PRISMA Health/ITOR, Greenville

Vključevanje udeležencevFaza 1

Starost 18 in več · Vsi spoli · Posodobljeno 21. sep. 2026 · NCT05983432

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Clinical Study Site, Greenville

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 18. sep. 2026 · NCT06767514

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

Carolina Urologic Research Center, Myrtle Beach

Vključevanje udeležencevOpazovalna študija

Starost 18 in več · Vsi spoli · Posodobljeno 14. sep. 2026 · NCT05059444

FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

Spartanburg Regional, Spartanburg

Vključevanje udeležencevFaza 1/2

Starost 18 in več · Vsi spoli · Posodobljeno 14. sep. 2026 · NCT06303505

Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors

MUSC Hollings Cancer Center, Charleston

Vključevanje udeležencevFaza 1/2

Starost 18 in več · Vsi spoli · Posodobljeno 9. sep. 2026 · NCT06750185

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Medical University of South Carolina, Charleston
Prisma Health Cancer Institute, Greenville
Lexington Medical Center, West Columbia

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 8. sep. 2026 · NCT06119581

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

Research Site, Greenville

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 4. sep. 2026 · NCT07291037

Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In

Medical University of South Carolina, Charleston

Vključevanje udeležencevFaza 3

Starost 18–90 · Vsi spoli · Posodobljeno 27. jul. 2026 · NCT06745908

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

AnMed Health Cancer Center, Anderson
Saint Joseph's/Candler - Bluffton Campus, Bluffton
Prisma Health Cancer Institute - Spartanburg, Boiling Springs
in še 9

Vključevanje udeležencevFaza 2

Starost 18 in več · Vsi spoli · Posodobljeno 3. jun. 2026 · NCT05642572

DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

USA03-0, Charleston

Vključevanje udeležencevFaza 2

Starost 18 in več · Vsi spoli · Posodobljeno 22. maj 2026 · NCT06953089

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

Ralph H Johnson VA Medical Center, Charleston

Vključevanje udeležencevFaza 2

Starost 18 in več · Vsi spoli · Posodobljeno 6. maj 2026 · NCT06116682

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

AnMed Health Cancer Center, Anderson
Saint Joseph's/Candler - Bluffton Campus, Bluffton
Medical University of South Carolina, Charleston
in še 5

Vključevanje udeležencevFaza 2/3

Starost 18 in več · Vsi spoli · Posodobljeno 5. maj 2026 · NCT06616584

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

AnMed Health Cancer Center, Anderson

Vključevanje udeležencevFaza 2

18 Minutes · Vsi spoli · Posodobljeno 5. maj 2026 · NCT06031688

Phase 2 Study of Fingolimod in Lung Cancers

Hollings Cancer Center at Medical University of South Carolina, Charleston

Vključevanje udeležencevFaza 2

Starost 18 in več · Vsi spoli · Posodobljeno 30. mar. 2026 · NCT06424067

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

AnMed Health Cancer Center, Anderson
Beaufort Memorial Hospital, Beaufort
Saint Joseph's/Candler - Bluffton Campus, Bluffton
in še 18

Vključevanje udeležencevOpazovalna študija

Starost 18 in več · Vsi spoli · Posodobljeno 17. mar. 2026 · NCT06418204

GEMINI-NSCLC: NSCLC Biomarker Study

The Medical University of South Carolina, Charleston

Vključevanje udeležencevOpazovalna študija

Starost 18 in več · Vsi spoli · Posodobljeno 5. feb. 2026 · NCT05236114

A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

Dren Investigational Site, Greenville

Vključevanje udeležencevFaza 1

Starost 18 in več · Vsi spoli · Posodobljeno 7. jan. 2026 · NCT06999187

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

Research Site 123, Charleston
Research Site 108, Greenville

Vključevanje udeležencevFaza 1/2

Starost 18 in več · Vsi spoli · Posodobljeno 21. nov. 2025 · NCT05914116

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Massive Bio SYNERGY-AI site, Greenville

Vključevanje udeležencevOpazovalna študija

Vse starosti · Vsi spoli · Posodobljeno 28. okt. 2025 · NCT03452774

Vir: ClinicalTrials.gov, podatki pridobljeni 6. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.